



Universiteit
Leiden
The Netherlands

The search for new treatment strategies for malignant pleural mesothelioma

Schunselaar, L.M.

Citation

Schunselaar, L. M. (2019, January 15). *The search for new treatment strategies for malignant pleural mesothelioma*. Retrieved from <https://hdl.handle.net/1887/67915>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/67915>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:

<http://hdl.handle.net/1887/67915>

Author: Schunselaar, L.M.

Title: The search for new treatment strategies for malignant pleural mesothelioma

Issue Date: 2019-01-15

Curriculum Vitae

Laurel Schunselaar was born on the 17th of August, 1987, in Enschede. After receiving her VWO diploma at the Bonhoeffer College van der Waalslaan in Enschede, she started her study Technical Medicine at the University of Twente in 2005. After obtaining her bachelor degree in 2008, she continued with her masters. During this master she followed four clinical research internships in which both research and clinical activities were the focus. She started at the Dutch Burn Centre in Beverwijk, after which she moved to Utrecht for the second and third internship at the department of trauma surgery and the department of orthopedics in the University Medical Center. During her internship at the Antoni van Leeuwenhoek in Amsterdam she became acquainted with screening chemotherapy on mesothelioma cells. For her master thesis project she stayed at the Antoni van Leeuwenhoek – Netherlands Cancer Institute and worked for one year on the development of short term primary tumor cultures of mesothelioma cells for screening and development of new therapeutic compounds. At the end of 2012 she obtained her master degree in Technical Medicine and started as a PhD student in the Antoni van Leeuwenhoek - Netherlands Cancer Institute. In the group of Prof. Dr Jacques Neeffjes and later Prof. Dr. Zwart, but always in close collaboration with the thoracic oncology group of Prof. Dr. Paul Baas, she worked on new treatment options for patients with mesothelioma. The results of this research are described in this thesis. Nowadays Laurel is working at the hematology department of the LUMC, where she is coordinating a clinical trial testing aclarubicin in AML patients.

List of publications

Schunselaar, LM. Monkhorst, K. Wijdeven, R. Peters, D. Zwart, W. Neeffjes, J. Baas, P. *Throphoblast Glycoprotein is Associated with Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.* J. Thorac Oncol. 2018 Oct. **13**(10): p.1577-1587

Quispel-Janssen, J. van der Noort, V. de Vries, JF. Zimmerman, M. Lalezari F. Thunissen, E. Monkhorst, K. Schouten, R. **Schunselaar, L.** Disselhorst, M. Klomp, H. Hartemink, K. Burgers, S. Buikhuisen, W. Baas, P. *Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.* J. Thorac Oncol. 2018 Oct. **13**(10): p. 1569-1576

Schunselaar, LM.* Quispel-Janssen, JMMF.* Kim, Y. Alifrangis, C. Zwart, W. Baas, P. Neeffjes, J. *Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses.* Clin Cancer Res. 2018 Apr. **24**(7): p. 1761-1770.

Quispel-Janssen JM,* Badhai J,* **Schunselaar L,*** Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neeffjes J, Alifrangis C. *Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition.* Clin Cancer Res. 2018 Jan. **24**(1): p. 84-94.

Schunselaar LM, Zwart W, Baas P. *Targeting BAP1: a new paradigm for mesothelioma.* Lung Cancer. 2017 Jul. **109**: p. 145-146.

Schunselaar LM, Quispel-Janssen JM, Neeffjes JJ, Baas P. *A catalogue of treatment and technologies for malignant pleural mesothelioma.* Expert Rev Anticancer Ther, 2016. **16**(4): p. 455-63.

Dankwoord

Het laatste onderdeel van mijn thesis wil ik graag gebruiken om mijn dank uit te spreken naar alle mensen die geholpen hebben dit boekje tot stand te brengen. Allereerst mijn promotoren en co-promotor, Sjaak, Paul en Wilbert, hartelijk dank voor jullie steun en begeleiding. Daarnaast mijn promotiecommissie, hartelijk dank voor het lezen van mijn proefschrift, Rob Hoeben, Huib Ovaa, Mario van der Stelt, Bob van der Water, Piet Postmus, Frank Baas, Dean Fennel, Marie Jose Goumans, Ilana Berlin en Sjaak Burgers. En natuurlijk mijn OIO commissie leden Reuven en Sjaak. Dank voor alle zetten in de juiste richting.

Aangezien onderzoek in je eentje een stuk saaier is wil ik graag al mijn collega's van het voormalige B6 cell biology II, het voormalige C2 molecular pathology, het huidige H5 oncogenomics en de thorax oncologie bedanken.

Als laatste wil ik graag mijn vrienden, schoonfamilie, ouders, zusje en broertje bedanken. Of het nu goed ging of iets minder bij jullie kon ik altijd mijn hart luchten. En natuurlijk, mijn grote liefde, Dennis zonder jou was dit alles niet gelukt.